- •
Neuroendocrine tumors of the lung represent a spectrum of low-grade typical carcinoid (TC), intermediate-grade atypical carcinoid (AC), and high-grade large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC).
- •
The most important histologic feature used to distinguish the grade of lung NE tumors is the mitotic count.
- •
Unlike in the gastrointestinal tract, Ki-67 is not established as a way to distinguish TC from AC. However, it is very useful for the separation of carcinoid
Pathology and Diagnosis of Neuroendocrine Tumors: Lung Neuroendocrine
Section snippets
Key points
Introduction: nature of the problem
Neuroendocrine (NE) tumors of the lung range from the low-grade typical carcinoid (TC) and intermediate-grade atypical carcinoid (AC) to the high-grade large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) (Box 1).1, 2 SCLC is the most common NE lung tumor, representing approximately 14% of invasive lung cancers.3 LCNEC represents about 3% of lung cancers in surgical series. Carcinoid tumors account for 1% to 2% of invasive lung malignancies. AC are the rarest of the
Molecular Changes in Pulmonary Neuroendocrine Tumors
Recent molecular studies by the Clinical Lung Cancer Genome Project (CLCGP) clearly show that carcinoids show relatively few genetic changes when compared with the high-grade SCLC and LCNEC, supporting the concept in the 2004 World Health Organization (WHO) classification that these are 2 very different groups of tumors.5 Both SCLC and LCNEC frequently show mutations in TP53, RB1, and EP300. Additional genetic changes, such as copy number, can be found in some LCNEC that are characteristic of
Clinical features
SCLC is the most common pulmonary NE tumor, with more than 30,000 cases anticipated to be diagnosed in the United States in 2014.11 There has been a decrease in the frequency of SCLC cases over the past 30 years in the United States from 17% to 13% of all lung cancers, according to the United States National Cancer Institute Surveillance, Epidemiologic, and End Results (SEER) database.3, 12 Most patients present with advanced disease, but in approximately 5% of cases tumors can present as a
Summary
There are 4 major NE lung tumors, but the TC and AC tumors belong to a different family from the high-grade SCLC and LCNEC according to histologic, clinical, epidemiologic, and genetic features. Pathologically these tumors are primarily distinguished based on the mitotic counts, presence or absence of necrosis, and cytologic features (Fig. 6).
References (43)
Advances in neuroendocrine lung tumors
Ann Oncol
(2010)- et al.
Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity
Ann Thorac Surg
(2004) - et al.
Prognostic significance of histopathologic subtype and stage in small cell lung cancer
Hum Pathol
(1992) Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas
Mod Pathol
(2012)- et al.
Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors
Mod Pathol
(2000) - et al.
Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung
Hum Pathol
(2001) - et al.
Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice
J Thorac Oncol
(2014) - et al.
Reproducibility of neuroendocrine lung tumor classification
Hum Pathol
(1998) - et al.
Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases
Hum Pathol
(1985) - et al.
Epidermal growth factor receptor mutations in small cell lung cancer: a brief report
J Thorac Oncol
(2011)
Pulmonary large cell carcinomas with neuroendocrine features are high-grade neuroendocrine tumors
Ann Thorac Surg
Cytological characteristics of pulmonary large cell neuroendocrine carcinoma
Lung Cancer
Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection
Ann Thorac Surg
What can we learn from the errors in the frozen section diagnosis of pulmonary carcinoid tumors? An evidence-based approach
Hum Pathol
TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location
Hum Pathol
Pathology and genetics: tumours of the lung, pleura, thymus and heart
Pulmonary neuroendocrine tumors: what (little) do we know?
J Natl Compr Canc Netw
A genomics-based classification of human lung tumors
Sci Transl Med
Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
Nature communications
Genetic changes in the spectrum of neuroendocrine lung tumors
Cancer
Cited by (96)
Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances
2023, Pathology Research and PracticePulmonary Carcinoid Tumorlet in the Explanted Lungs for Lung Transplantation: A Case Series of 15 Patients
2023, Transplantation ProceedingsNovel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review
2022, Seminars in Cancer BiologyEpidemiological analysis of lung and mediastinal neuroendocrine neoplasms in Japan based on the national database
2022, Cancer EpidemiologyCitation Excerpt :Furthermore, the second most prevalent and least prevalent subtype of the remaining subtypes also varied: LCNECs (10%) and NETs (3%) in the lungs, and NETs (39%) and LCNECs (14%) in the mediastinum. Although the distribution of lung NENs was almost similar to that in previous studies (SCCs, 79%; LCNECs, 16%; NETs, 5%) [15,16], the distribution of mediastinal NENs in our study was inconsistent with previous studies. Ose et al. reported that the commonest subtype of mediastinal NENs was NETs (60%), followed by SCCs (30%), and LCNECs (10%) [17].
Cytopathology in the diagnosis, treatment and management of malignant respiratory disease
2021, Diagnostic HistopathologyCitation Excerpt :These are typical carcinoid tumour, atypical carcinoid tumour and large cell neuroendocrine tumour. There is not the space to discuss these in detail and there have been a number of excellent reviews13,14 but a couple of points may be useful: Carcinoid tumour is usually encountered in fine needle aspirate (FNA) preparations of primary or metastatic lesions.